Tumor Cell Clearance Reimagined

About CERo

At the intersections of innate and adaptive cell clearance, molecular and cellular therapy lies CERo

At CERo, we are expanding the armamentarium of engineered cell therapies to create a whole new class of innovative medicines for cancer patients. Armed with an understanding of cellular clearance and molecular immunology, we engineer cells to engage new and complementary cell elimination pathways to enable deeper and more sustained clinical responses.

Our Science


Coordinating cell clearance to eliminate tumors

We believe that combining multiple forms of cell clearance into single cells will vastly expand their therapeutic potential. Our team leverages understandings from innate immune clearance and synthetic biology to engineer cells with expanded capabilities to eliminate tumors.


Creating synergies with targeted therapeutics

We rationally integrate engineered cells with medicines directed at precisely defined molecular targets to create powerful therapeutic synergies. We believe targeting multiple components of disease simultaneously will enable more complete and durable clinical responses.


Enhancing secondary immune responses

To further enhance the body’s ability to recognize diseased cells, we engineer cells to uniquely capture antigen and mobilize powerful adaptive immune responses to secondary target antigens. Broadening of immune responses over time evokes ongoing and adaptable tumor control.


Collaboration across disciplines

Our team combines the languages of innate, adaptive, molecular-targeted, and computational learnings together to generate and leverage data today to advance tomorrow’s cell therapy platforms.


Our Leadership


Daniel Corey, MD

Founder, Chief Executive Officer

Dr. Daniel Corey serves as Chief Executive Officer. A board-certified hematologist, Dr. Corey trained at Duke University’s School of Medicine and Stanford University’s School of Medicine. Dr. Corey led the foundational discovery efforts to identify and define the therapeutic utility of the CER-T platform. His previous work focused on advancing understanding of the basic biology of innate immune responses and their contributions to tumor resistance and relapse.

John Rossi, M Sci

Head of Translational Medicine

Mr. Rossi leads the Translational Medicine team at CERo. Prior to joining, Mr. Rossi was Senior Director of Translational Medicine and Head of Cell Therapy Clinical Pharmacology at Kite, a Gilead Company. While at Kite, Mr. Rossi led translational activities supporting the clinical development and global approvals of Yescarta® and Tecartus® CAR T cell therapies. Mr. Rossi’s team also supported work focusing on the mechanistic understanding of engineered cell therapy products under strategic collaborations with the NCI and numerous leading academic institutions. Before Kite, Mr. Rossi spent 13 years in oncology drug development at Amgen working with teams to identify novel biomarkers for hematologic and solid tumor drug development programs.


Remus Vezan, MD, PhD

Chief Medical Officer

Dr. Vezan serves as Chief Medical Officer. Prior to CERo, Dr. Vezan was Executive Director of Clinical Development and Product Clinical Lead for Yescarta and subsequently Tecartus at Kite where he oversaw the clinical development of +20 CAR T-cell trials. Before Kite, Dr. Vezan was Medical Director at Pharmacyclics. Dr. Vezan completed his medical training (M.D., Ph.D.) at the University of Medicine and Pharmacy Cluj, Romania and University of Bern, Switzerland.

Jordan Corey, CFA

Chief Financial Officer

Mr. Corey serves as Chief Financial Officer. Prior to CERo, Mr. Corey was Vice President of Finance and Investor Relations at Vir Biotechnology. Before Vir, Mr. Corey worked on the investment team at the family office of Bill and Melinda Gates. He received an M.B.A. from U.C. Berkeley’s Haas School of Business and is a CFA Charter-holder.

Board of Directors


Daniel Corey, MD

Director

Dr. Daniel Corey serves as Chief Executive Officer. A board-certified hematologist, Dr. Corey trained at Duke University’s School of Medicine and Stanford University’s School of Medicine. Dr. Corey led the foundational discovery efforts to identify and define the therapeutic utility of the CER-T platform. His previous work focused on advancing understanding of the basic biology of innate immune responses and their contributions to tumor resistance and relapse.

Stanley Ridell, MD

Director

Dr. Riddell is a Faculty member at the Fred Hutchinson Cancer Research Center, the University of Washington, Chair of the Research and Development Executive Committee at Lyell Immunopharma, Inc, and Co-founder of Juno Therapeutics.


Stuart Sloan

Director

Mr. Sloan is the Founder of Sloan Capital Companies, previously served as a Director of the Marsha Rivkin Center for Ovarian Cancer Research in Seattle and as a Director of the Swedish Medical Center. He has been a founder, investor, senior executive, and board member of a number of companies and at different stages in their corporate growth, including Shuck’s Auto Supply, Quality Food Centers, J Crew, and Anixter International.

Heather Turner

Director

Ms. Turner is Senior Vice President & General Counsel at Lyell Immunopharma, Inc.  She has extensive industry experience providing legal guidance to public and private biotechnology companies as well as working in/supporting portfolio strategy, medical affairs, government affairs and human resources functions.


Larry Corey, MD

Co-founder, Head of Scientific Advisory Board, Board Observer

Dr. Corey is a member and past President of the Fred Hutchinson Cancer Research Center, Director of the Covid-19 Prevention Network, member of the National Academy of Medicine, and a co-founder of Juno Therapeutics and Vir Biotechnology.

Rick Klasuner, MD

Scientific Advisor, Board Observer

Dr. Klausner is the founder and executive chairman of Lyell Immunopharma, past director of the National Cancer Institute, Chief Medical Officer at Illumina, co-founder and director of Grail, and co-founder and director of Juno Therapeutics.

Partners

Investors

Join our exceptional team

If you want to help lead the way to develop more effective medicines for some of our most challenging oncology indications, check out our openings or contact us. Our team is comprised of an ambitious group of physicians, life scientists, data scientists, and synthetic biologists working together to problem solve the most difficult-to-treat cancers.

job openings

Contact Us

CERo Therapeutics, Inc.
279 East Grand Ave, Suite 410
South San Francisco, CA 94080

info@cero.bio